Alexion Gets European Approval for Soliris in Nervous-System Disorder
August 27 2019 - 9:48AM
Dow Jones News
By Colin Kellaher
Alexion Pharmaceuticals Inc. (ALXN) on Tuesday said the European
Commission extended the approval of Soliris to include adults with
a rare disease of the central nervous system.
The Boston biopharmaceutical company said Soliris is now the
only approved medication in Europe for the treatment of
neuromyelitis optica spectrum disorder in adults who are
anti-aquaporin-4 antibody positive with a relapsing course of the
disease.
The European Medicines Agency's Committee for Medicinal Products
for Human Use last month recommended extending approval of Soliris
for the disorder.
The U.S. Food and Drug Administration approved Soliris for the
indication in June.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 27, 2019 09:33 ET (13:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Sep 2023 to Sep 2024
